Compare
Cytokinetics vs Gilead Sciences (CYTK vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Cytokinetics (CYTK) returned -9.3% and Gilead Sciences (GILD) +36.1%; so far this year the figures are -15.5% and +36.0%.
Gilead Sciences is the larger company by market value, about 27.7 times the size of Cytokinetics.
Revenue grew +29.9% at CYTK and +6.5% at GILD over the last year.
CYTK pays no dividend. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| CYTK | GILD | |
|---|---|---|
| Price | $53.69 | $166.89 |
| 1-day | -3.35% | -0.41% |
| YTD | -15.50% | +35.97% |
| 1 year | -9.29% | +36.15% |
| 3 years | +52.96% | +108.12% |
| Market cap | $7.5B | $207.0B |
| P/E | — | — |
| P/S | 66.02 | 6.68 |
| P/B | — | 15.87 |
| Revenue growth | +29.90% | +6.50% |
| EPS growth | — | -149.00% |
| Gross margin % | — | 79.9 |
| Net margin % | -686.6 | -12.5 |
| ROE % | — | -29.6 |
| Debt / equity | — | 2.01 |
| FCF yield % | -7.9 | 6.7 |
| Dividend yield % | — | 1.95 |
| Beta | 0.99 | 0.37 |
| RSI (14) | 27.0 | 60.2 |
| Technical rating |